Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CertaraCERT -3.44%65 Cash-to-Debt is 0.62 as of Jun. 2026, which is 6% below its 10-year median of 0.66. GuruFocus rates CERT with a GF Score™ of 65/100 and a GF Value™ of $12.36 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 663 Healthcare Providers & Services companies, Certara ranks worse than 54.6% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Certara's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.62.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Certaracouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Certara's Cash-to-Debt or its related term are showing as below:
CERT'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03 Med: 0.66 Max: 1.41
Current: 0.62
During the past 8 years, Certara's highest Cash to Debt Ratio was 1.41. The lowest was 0.03. And the median was 0.66.
CERT's Cash-to-Debt is ranked worse than 54.6% of 663
companies
in the Healthcare Providers & Services industry
Industry Median: 0.77
vs CERT: 0.62
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Certara Cash-to-Debt Related Terms
Certara Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Certara's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Health Information Services subindustry, Certara's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Certara Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Certara's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Certara's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Certara (CERT) has a Cash-to-Debt of 0.62 as of Jun. 2026. This is near median its historical median of 0.66. Over the past decade, Certara's Cash-to-Debt has ranged from 0.03 to 1.41. According to the industry distribution chart, Certara ranks #362 out of 663 companies in the Healthcare Providers & Services industry, placing it in the top 54.6%.
Is Certara's Cash-to-Debt too high?
Certara's current Cash-to-Debt of 0.62 is near median its 10-year median of 0.66. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 1.41. The Healthcare Providers & Services industry median Cash-to-Debt is 0.77. Certara's value of 0.62 is 19.5% below this industry median. Based on the distribution chart, Certara ranks #362 out of 663 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Certara has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Certara's Cash-to-Debt compare to SDGR and OMDA?
According to the Healthcare Providers & Services industry distribution chart, Certara ranks #362 out of 663 companies for Cash-to-Debt. This places Certara in the lower half of its industry. The industry median Cash-to-Debt is 0.77. Certara's value of 0.62 is 19.5% below this benchmark. Historically, Certara's own Cash-to-Debt has ranged from 0.03 to 1.41 over the past decade. While the company's 10-year median is 0.66 vs. the industry median of 0.77, Certara has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.77, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Certara's current Cash-to-Debt of 0.62 is 19.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Certara's current Cash-to-Debt is 0.62, which is near median its own 10-year median of 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Certara stock overvalued right now?
Based on GuruFocus' analysis, Certara (CERT) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.36, compared to a current price of $8.44 — trading 31.8% below its estimated fair value. The current Cash-to-Debt is 0.62, which is near median its 10-year median of 0.66 and 19.5% below the Healthcare Providers & Services industry median of 0.77. Certara's overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Certara (CERT), the current Cash-to-Debt is 0.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Certara (CERT) Overvalued in 2026?
Based on GuruFocus' analysis, Certara stock appears to be undervalued.
The current stock price of $8.44 is trading 31.8% below its estimated GF Value™ of $12.36.
GuruFocus considers Certara to be Significantly Undervalued.
Key valuation signals for CERT:
Cash-to-Debt: 0.62 (near median its 10-year median of 0.66)
GF Value™: $12.36 vs. price of $8.44 (31.8% below fair value)
Industry Position: 19.5% below the Healthcare Providers & Services median (#362 of 663)
No single metric tells the full story. See the CERT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
65GF Score
Get the complete analysis for CERT
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CERT has been successfully added to your 
